Erythropoietin and Soluble Erythropoietin Receptor: A Role for Maternal Vascular Adaptation to High-Altitude Pregnancy.
An imbalance of proangiogenic and antiangiogenic factors is thought to induce the widespread vascular dysfunction characteristic of preeclampsia (PreE). Erythropoietin (Epo), a pleiotropic cytokine, has important angiogenic and vasoactive properties; however, its contribution to maternal vascular dysfunction in PreE is unknown.



Because high altitude (HA) raises the incidence of PreE, we asked whether HA increased maternal Epo and soluble Epo receptor (sEpoR) levels and whether such effects differed between PreE and normotensive controls at HA.



Longitudinal studies were conducted in pregnant Andean residents at HA (n = 28; 3600 m) or sea level (SL; n = 16; 300 m). Cross-sectional studies included 34 gestational age‒matched Andean PreE cases (n = 17) and controls (n = 17) in La Paz-El Alto, Bolivia (3600 to 4100 m).



HA augmented the pregnancy-associated rise in Epo relative to SL (P = 0.002), despite similar reductions in hemoglobin (Hb) across pregnancy at each altitude (7% to 9%, P < 0.001 for both). HA PreE cases had circulating Epo levels equivalent to those of controls but greater sEpoR (P < 0.05) and reduced Hb (P = 0.06, trend).



Our findings suggest that an augmented pregnancy-associated rise in Epo may be important for successful vascular adaptation to pregnancy at HA. We further speculate that the elevated sEpoR observed in PreE vs controls at HA impedes the effect of Epo to maintain endothelial function and may, in turn, be of pathological relevance for PreE at HA.
Departments of Medicine.
Gabriel H
GH
Wolfson
Bolivian Institute of High Altitude Biology, La Paz, Bolivia.
Enrique
E
Vargas
Emergency Medicine, and.
Vaughn A
VA
Browne
Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado 80045; and.
Lorna G
LG
Moore
Departments of Medicine.
Colleen G
CG
Julian
D000222:Adaptation, Physiological; D000328:Adult; D000531:Altitude; D015415:Biomarkers / Q000032:analysis; D001838:Bolivia / Q000453:epidemiology; D002140:California / Q000453:epidemiology; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D011379:Prognosis; D017467:Receptors, Erythropoietin / Q000097:blood*; D014652:Vascular Diseases / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*
D015415:Biomarkers; D017467:Receptors, Erythropoietin; D004921:Erythropoietin